StreetInsider.com News Articles

Piper Sandler's Spine Doc Survey Results: 'We favor ATEC and GMED as our top picks'

Thu, 09 Jul 2026 10:30:40 -0400

Piper Sandler analyst Matt O'Brien weighs in on the spine space following the Spine Doc Survey.

The analyst commented: "We surveyed 30 spine surgeons that perform at least 75 cases annually and were very pleased to hear a high majority of them say procedure volumes have been steady the past three months and the outlook for the remainder of the year is positive too. They expect to perform more robotically-assisted cases in the future, with GMED and MDT the standouts here. Feedback on the new MDT robot was really good, which is a clear positive for them, and a number of

Piper Sandler's Spine Doc Survey Results: 'We favor ATEC and GMED as our top picks'

Thu, 09 Jul 2026 10:30:40 -0400

Piper Sandler analyst Matt O'Brien weighs in on the spine space following the Spine Doc Survey.

Piper Sandler's Spine Doc Survey Results: 'We favor ATEC and GMED as our top picks'

Thu, 09 Jul 2026 10:30:40 -0400

Piper Sandler analyst Matt O'Brien weighs in on the spine space following the Spine Doc Survey.

Piper Sandler's Spine Doc Survey Results: 'We favor ATEC and GMED as our top picks'

Thu, 09 Jul 2026 10:30:40 -0400

Piper Sandler analyst Matt O'Brien weighs in on the spine space following the Spine Doc Survey.

Piper Sandler's Spine Doc Survey Results: 'We favor ATEC and GMED as our top picks'

Thu, 09 Jul 2026 10:30:40 -0400

Piper Sandler analyst Matt O'Brien weighs in on the spine space following the Spine Doc Survey.

Piper Sandler's Spine Doc Survey Results: 'We favor ATEC and GMED as our top picks'

Thu, 09 Jul 2026 10:30:40 -0400

Piper Sandler analyst Matt O'Brien weighs in on the spine space following the Spine Doc Survey.

Needham Starts Carlsmed Inc (CARL) at Buy

Wed, 01 Jul 2026 05:42:11 -0400

Needham analyst David Saxon initiates coverage on Carlsmed Inc (NASDAQ: CARL) with a Buy rating and a price target of $17.00.

The analyst comments "We are initiating coverage with a Buy rating and a $17 price target as we believe CARL's personalized aprevo implants are differentiated vs. traditional stock spine implants. Given attractive clinical data showing lower revision rates to stock implants, in addition to favorable facility reimbursement, we expect CARL to see broader adoption, with our physician calls suggesting strong utilization growth. We believe this can allow CARL to sustain its high-growth profile and help it progress towards profitability."

For an

Needham Starts Carlsmed Inc (CARL) at Buy

Wed, 01 Jul 2026 05:42:11 -0400

Needham analyst David Saxon initiates coverage on Carlsmed Inc (NASDAQ: CARL) with a Buy rating and a price target of $17.00.

For an

Form 4 CARLSMED, INC. For: Jun 03 Filed by: OBOYLE KEVIN C

Mon, 22 Jun 2026 06:14:00 -0400

si-local-file:///var/storage/secattach/20260622/26669460.html

Form 4 CARLSMED, INC. For: Jun 03 Filed by: OBOYLE KEVIN C

Mon, 22 Jun 2026 06:14:00 -0400

si-local-file:///var/storage/secattach/20260622/26669460.html

Form 4 CARLSMED, INC. For: Jun 03 Filed by: Sidow Kevin

Mon, 22 Jun 2026 06:11:00 -0400

si-local-file:///var/storage/secattach/20260622/26669452.html

Form 4 CARLSMED, INC. For: Jun 03 Filed by: Sidow Kevin

Mon, 22 Jun 2026 06:11:00 -0400

si-local-file:///var/storage/secattach/20260622/26669452.html

Form 4 CARLSMED, INC. For: Jun 03 Filed by: YOUNG PHILIP M

Mon, 22 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260622/26669363.html

Form 4 CARLSMED, INC. For: Jun 03 Filed by: YOUNG PHILIP M

Mon, 22 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260622/26669363.html

Form 4 CARLSMED, INC. For: Jun 03 Filed by: ROOT JONATHAN D

Mon, 22 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260622/26669364.html

Form 4 CARLSMED, INC. For: Jun 03 Filed by: ROOT JONATHAN D

Mon, 22 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260622/26669364.html

Form 8-K CARLSMED, INC. For: Jun 03

Wed, 03 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260603/26598767.html

Form 8-K CARLSMED, INC. For: Jun 03

Wed, 03 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260603/26598767.html

Carlsmed, Inc. (CARL) Tops Q1 EPS by 5c

Tue, 05 May 2026 18:09:06 -0400

Carlsmed, Inc. (NASDAQ: CARL) reported Q1 EPS of ($0.32), $0.05 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $16.1 million.

For earnings history and earnings-related data on Carlsmed, Inc. (CARL) click here.

Form 10-Q CARLSMED, INC. For: Mar 31

Tue, 05 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260505/26434771.html

Form 10-Q CARLSMED, INC. For: Mar 31

Tue, 05 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260505/26434771.html

Form 8-K CARLSMED, INC. For: May 05

Tue, 05 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260505/26434506.html

Form 8-K CARLSMED, INC. For: May 05

Tue, 05 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260505/26434506.html

Carlsmed® Reports First Quarter 2026 Financial Results

Tue, 05 May 2026 16:01:00 -0400

First quarter 2026 revenue of $16.1 million, representing 58% growth year-over-year

Full year 2026 revenue guidance raised to $72 million to $77 million

CARLSBAD, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the first quarter ended March 31, 2026.

“We began 2026 with strong momentum, delivering 58% year-over-year revenue growth, publishing meaningful clinical data, and debuting new products to continue to advance our mission of improved patient outcomes

Carlsmed® Reports First Quarter 2026 Financial Results

Tue, 05 May 2026 16:01:00 -0400

First quarter 2026 revenue of $16.1 million, representing 58% growth year-over-year

Full year 2026 revenue guidance raised to $72 million to $77 million